Phase 3 trial of denosumab for bone metastases in hormone-refractory prostate cancer
Amgen announced results from its Phase 3, head-to-head trial that compared denosumab to Zometa (zoledronic acid, from Novartis) in 1,901 patients with bone metastases from hormone-refractory prostate cancer.
